| Variable | N | Overall, N = 2,3301 | Treatment Received | p-value2 | |
|---|---|---|---|---|---|
| Neoadjuvant Multiagent Chemotherapy, N = 1,7021 | Postop Multiagent Chemotherapy, N = 6281 | ||||
| Age | 2,330 | 63 (56, 69) | 63 (56, 70) | 62 (54, 69) | 0.035 |
| Sex | 2,330 | 0.3 | |||
| Female | 1,130 (48%) | 837 (49%) | 293 (47%) | ||
| Male | 1,200 (52%) | 865 (51%) | 335 (53%) | ||
| Race | 2,330 | 0.2 | |||
| Black | 177 (7.6%) | 120 (7.1%) | 57 (9.1%) | ||
| Other | 108 (4.6%) | 76 (4.5%) | 32 (5.1%) | ||
| White | 2,045 (88%) | 1,506 (88%) | 539 (86%) | ||
| Type of Insurance | 2,330 | 0.013 | |||
| Medicaid | 110 (4.7%) | 79 (4.6%) | 31 (4.9%) | ||
| Medicare | 952 (41%) | 697 (41%) | 255 (41%) | ||
| Not Insured | 36 (1.5%) | 17 (1.0%) | 19 (3.0%) | ||
| Private Insurance/Managed Care/Goverment | 1,199 (51%) | 885 (52%) | 314 (50%) | ||
| Unknown | 33 (1.4%) | 24 (1.4%) | 9 (1.4%) | ||
| Regions | 2,330 | 0.4 | |||
| Midwest | 639 (27%) | 456 (27%) | 183 (29%) | ||
| Northeast | 569 (24%) | 433 (25%) | 136 (22%) | ||
| South | 686 (29%) | 499 (29%) | 187 (30%) | ||
| Unknown | 35 (1.5%) | 24 (1.4%) | 11 (1.8%) | ||
| West | 401 (17%) | 290 (17%) | 111 (18%) | ||
| Income | 2,330 | 0.2 | |||
| < $38,000 | 289 (12%) | 196 (12%) | 93 (15%) | ||
| >=$63,000 | 893 (38%) | 662 (39%) | 231 (37%) | ||
| $38,000-$47,999 | 492 (21%) | 362 (21%) | 130 (21%) | ||
| $48,000-$62,999 | 647 (28%) | 474 (28%) | 173 (28%) | ||
| Unknown | 9 (0.4%) | 8 (0.5%) | 1 (0.2%) | ||
| No High School Degree | 2,330 | 0.037 | |||
| <7.0% | 718 (31%) | 541 (32%) | 177 (28%) | ||
| >=21.0% | 242 (10%) | 166 (9.8%) | 76 (12%) | ||
| 13.0-20.9% | 508 (22%) | 351 (21%) | 157 (25%) | ||
| 7.0-12.9% | 854 (37%) | 637 (37%) | 217 (35%) | ||
| Unknown | 8 (0.3%) | 7 (0.4%) | 1 (0.2%) | ||
| Population Density | 2,330 | 0.6 | |||
| Metro | 1,899 (82%) | 1,381 (81%) | 518 (82%) | ||
| Rural | 44 (1.9%) | 33 (1.9%) | 11 (1.8%) | ||
| Unknown | 53 (2.3%) | 43 (2.5%) | 10 (1.6%) | ||
| Urban | 334 (14%) | 245 (14%) | 89 (14%) | ||
| Charlson-Deyo Score | 2,330 | 0.5 | |||
| >=3 | 41 (1.8%) | 34 (2.0%) | 7 (1.1%) | ||
| 0 | 1,640 (70%) | 1,191 (70%) | 449 (71%) | ||
| 1 | 543 (23%) | 397 (23%) | 146 (23%) | ||
| 2 | 106 (4.5%) | 80 (4.7%) | 26 (4.1%) | ||
| TNM Clin T | 2,330 | ||||
| c0 | 2 (<0.1%) | 1 (<0.1%) | 1 (0.2%) | ||
| c1 | 35 (1.5%) | 9 (0.5%) | 26 (4.1%) | ||
| c2 | 184 (7.9%) | 86 (5.1%) | 98 (16%) | ||
| c3 | 1,227 (53%) | 1,000 (59%) | 227 (36%) | ||
| c4 | 657 (28%) | 564 (33%) | 93 (15%) | ||
| cX | 218 (9.4%) | 40 (2.4%) | 178 (28%) | ||
| Unknown | 7 (0.3%) | 2 (0.1%) | 5 (0.8%) | ||
| TNM Clinical N | 2,330 | <0.001 | |||
| c0 | 1,388 (60%) | 1,086 (64%) | 302 (48%) | ||
| c1 | 694 (30%) | 544 (32%) | 150 (24%) | ||
| cX | 241 (10%) | 70 (4.1%) | 171 (27%) | ||
| Unknown | 7 (0.3%) | 2 (0.1%) | 5 (0.8%) | ||
| Clinical Downstaging | 2,330 | <0.001 | |||
| No | 955 (41%) | 667 (39%) | 288 (46%) | ||
| Unknown | 677 (29%) | 356 (21%) | 321 (51%) | ||
| Yes | 698 (30%) | 679 (40%) | 19 (3.0%) | ||
| Surgery Type | 2,330 | 0.003 | |||
| Pancreatectomy, NOS | 27 (1.2%) | 16 (0.9%) | 11 (1.8%) | ||
| Partial pancreatectomy, distal | 312 (13%) | 219 (13%) | 93 (15%) | ||
| Total | 280 (12%) | 214 (13%) | 66 (11%) | ||
| Unknown | 134 (5.8%) | 82 (4.8%) | 52 (8.3%) | ||
| Whipple | 1,577 (68%) | 1,171 (69%) | 406 (65%) | ||
| Surgical Margins | 2,330 | <0.001 | |||
| R0 | 1,563 (67%) | 1,264 (74%) | 299 (48%) | ||
| R1 | 358 (15%) | 197 (12%) | 161 (26%) | ||
| R2 | 40 (1.7%) | 13 (0.8%) | 27 (4.3%) | ||
| Unknown | 369 (16%) | 228 (13%) | 141 (22%) | ||
| Tumor Grade | 2,330 | <0.001 | |||
| Moderately differentiated | 682 (29%) | 443 (26%) | 239 (38%) | ||
| Poorly differentiated | 524 (22%) | 304 (18%) | 220 (35%) | ||
| Unknown | 945 (41%) | 834 (49%) | 111 (18%) | ||
| Well differentiated, differentiated | 179 (7.7%) | 121 (7.1%) | 58 (9.2%) | ||
|
1
Mean (SD))
2
Statistical tests performed: Wilcoxon rank-sum test; chi-square test of independence; Fisher's exact test
|
|||||